The Authors Reply:  by Singer, Eugenia et al.
Does urinary neutrophil
gelatinase-associated lipocalin
really solve the issue of
discriminating prerenal from
intrinsic acute kidney injury?
To the Editor: Singer et al.1 reported on the diagnostic value
of urinary neutrophil gelatinase-associated lipocalin (uNGAL)
in the discrimination of intrinsic and prerenal acute kidney
injury (AKI), concluding that uNGAL signiﬁcantly improves
diagnostic capacity. For several reasons, we feel that this
conclusion might be overoptimistic.
First, a biomarker would be most valuable when there is
doubt about the correct diagnosis of intrinsic vs. prerenal
AKI. Currently, this differential diagnosis is made on the
basis of patient history, volume status, the use of nephrotoxic
medications, and so on; using this approach as the gold
standard, no clear differential diagnosis could be made in a
substantial number of cases (38 out of 145); however, in this
group, uNGAL was not able to make a discrimination as well.
Thus, uNGAL is not helping in the discrimination in those
patients in whom it would be most needed. Second, the
diagnostic accuracy of the multivariate model increases only
modestly from 68.3 to 74.5 % when uNGAL is added. It
would have been interesting to see the effect of inclusion
of other parameters, such as urinary volume or evolution of
serum creatinine in the ﬁrst 4 h of admission.
Third, the authors use a composite end point, including
factors with a substantially different impact: mortality was put
at the same level as renal replacement therapy and step-up of
RIFLE class.
Fourth, authors use RIFLE rather than the Acute Kidney
Injury Network classiﬁcation.2 In contrast to the former,
the latter requires that patients be volume-repleted. If
the authors1 would have applied this strategy, they would
probably already have distinguished the majority of the
prerenal cases, as is obvious from Figure 2, in which it can
clearly be seen that serum creatinine is decreasing in the
prerenal subjects. Furthermore, the additional discriminatory
value of uNGAL would be less than that presented in the
current analysis.
In conclusion, we believe that the paper by Singer et al1
does not change the message that the diagnostic value of
uNGAL is overoptimistic.3 Advocating the use of uNGAL
might lead to neglecting other important clinical criteria.
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The Authors Reply: We thank Drs Van Biesen et al.1 for
their letter regarding our study where they question the
diagnostic utility of determining urinary neutrophil gelati-
nase-associated lipocalin (uNGAL) in patients that present
with elevated serum creatinine. Among physicians, nephrol-
ogists are particularly aware that the disease phenotype is
critically time-dependent as patients can be, e.g., in positive
sodium balance without edema, or in complete renal failure
with ‘normal’ serum creatinine. In addition, decreases in
glomerular ﬁltration rate are part of the normal homeostatic
response to marked reductions of extracellular ﬂuid volume
and also to the neurohumoral response triggered by diseases
in which cardiovascular homeostasis is compromised, i.e.,
congestive heart failure, hypoalbuminemia, and so on. In all
these conditions, serum creatinine can be elevated and
whether this is due to an appropriate renal response to
neurohumoral signals (i.e., prerenal) or to an intrinsic acute
kidney injury (AKI) has vexed physicians and nephrologists
for decades. Indeed, true distinctions of ‘prerenal’ vs.
‘intrinsic renal’ increases in plasma creatinine are only
made retrospectively depending on the patient’s response
to therapy. Moreover, in rich societies ‘prerenal’ increases
in plasma creatinine are most often due to abnormal
cardiovascular function so that acute administration of
volume is often not indicated. Given these complexities,
development of a test that immediately assists the physician
confronting a patient with an elevated serum creatinine would
be highly valuable. Our study now adds to a growing body of
evidence supporting the concept that NGAL correlates with
processes that induce intrinsic AKI, but not with transient
pre-renal elevations of creatinine.2–4
Speciﬁcally, Van Biesen et al.1 suggested that a volume-
repleted study population should have been selected, but this
would have obscured our intention to test the prospective
discriminatory ability of uNGAL. Furthermore, we would
imagine that 4-h repeat measurements of urinary output and
serum creatinine would be neither sensitive nor compatible
with rapid triage. Moreover, similar to previous studies,4,5
NGAL predicted poor clinical outcomes whether mortality was
included into a composite outcome (our paper) or only renal-
speciﬁc outcomes were considered (Table 1). Van Biesen et al.1
are particularly concerned with the utility of uNGAL in
patients who were unclassiﬁable. We point out that we aimed
to make gold standard diagnoses of prerenal and intrinsic AKI,
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which required the exclusion of ambivalent cases. As detailed
in our paper, some were unclassiﬁable because of exposure to
additional renal stressors (e.g., nephrotoxins) after enrollment,
which altered the relationships between initial urine sampling
and subsequent serum creatinine dynamics and outcomes.
Accordingly, neither serum creatinine nor uNGAL were
predictive of clinical outcomes in this sub-population. Whether
uNGAL discriminated intrinsic AKI correctly in these
unclassiﬁable patients simply could not be assessed based on
our strict, a priori deﬁnitions of prerenal and intrinsic AKI.
In sum, we consider uNGAL a promising candidate
marker to address the unquestionable limitations of using
serum creatinine as a sole marker of intrinsic kidney damage.
Larger studies with a multicentric design will soon be avail-
able to further address the potential of NGAL in situations
that demand prospective data.
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Warfarin-related nephropathy
To the Editor: In the July (2) 2011 issue, Brodsky et al.1
purport to demonstrate the consequences of warfarin-related
nephropathy (WRN) among a retrospective cohort from
the Ohio State University Medical Center. The cohort
selection procedure was designed to yield cases of ‘pre-
sumptive’ WRN, but may have resulted in selection bias:
patients who had a creatinine measured within 1 week of an
international normalized ratio (INR) 43 were selected. It is
possible that the selection regimen produced a cohort
enriched in subjects with acute illnesses, and it was the latter,
rather than ‘WRN’, that was responsible for the rise in serum
creatinine. In support of this alternative hypothesis is the fact
that ‘WRN’ cases had more frequent preexisting heart failure
and chronic kidney disease, which would leave them prone
to acute deterioration. The mortality hazard associated with
‘WRN’ was concentrated within the ﬁrst few weeks after the
initial INR elevation, which is consistent with the alter-
native hypothesis. The latter would also explain why drugs
expected to both increase and decrease glomerular capillary
pressure were associated with ‘WRN’, as both would tend
to be used in patients who are acutely ill. Further, the analysis
was restricted to only the ﬁrst INR elevation. One would
expect the latter to select for patients new to anticoagulation
therapy or those who had started other medications that
interfered with anticoagulant metabolism. In both cases, the
sampling would select for patients with acute illness. Thus,
the observed association between the creatinine elevation
(presumptive WRN) and mortality risk may have been
confounded.
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Table 1 |Multiple logistic regression models for the
prediction of a composite renal outcome (step-up in RIFLE
severity class or dialysis initiation)
Parameter P-value Odds ratioa R2-value AUC–ROCa
Biomarker model
Age (470 years) 0.171 0.6 (0.2–1.3) 0.189 0.74 (0.63–0.85)
Serum creatinine
(4205mmol/l)
0.048 2.4 (1.0–5.6)
Urinary NGAL
(4104mg/l)
0.002 4.3 (1.7–10.5)
Conventional model
Age (470 years) 0.151 0.6 (0.2–1.2) 0.081 0.66 (0.55–0.76)
Serum creatinine
(4205mmol/l)
0.021 2.7 (1.2–6.1)
Abbreviations: AUC, area under the curve; NGAL, neutrophil gelatinase-associated
lipocalin; RIFLE, risk, injury, failure, loss, end-stage renal disease; ROC, receiver
operating characteristic.
aData in parentheses are 95% confidence intervals.
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